Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference
Finch Therapeutics Group announced that CEO Mark Smith, PhD, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET. The event will be available via a live webcast on Finch's website, with a replay accessible for 30 days post-event.
Finch focuses on microbiome therapeutics, including its lead candidate, CP101, which targets recurrent C. difficile infections and has received FDA designations for expedited development. The company is also advancing treatments for chronic hepatitis B and autism spectrum disorder.
- None.
- None.
SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 2:45 pm ET.
A live webcast will be available under the ‘Investors & News’ section of the Finch website. A replay of the webcast will become available approximately three hours after the event and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
Media Contact:
Gabriella Linville-Engler
media@finchtherapeutics.com
Investor Contact:
Greg Perry
ir@finchtherapeutics.com
FAQ
When is the BofA Securities 2021 Virtual Health Care Conference for FNCH?
Who is speaking at the BofA Securities conference for FNCH?
How can I watch the FNCH conference live?
What is CP101 being developed for by FNCH?
What FDA designations has FNCH received for CP101?
What are other diseases FNCH is targeting?
